Matthias Preusser, Professor and Head of Medical Oncology at the Medical University of Vienna, shared on LinkedIn:
“Neuro-Oncology Trial Spotlight:
Can re-irradiation improve survival in patients with recurrent glioblastoma? The ongoing pragmatic and EU-funded LEGATO trial aims to answer this relevant clinical question.
Study Title:
- Lomustine with or without reirradiation for first progression of glioblastoma (LEGATO, EORTC-2227-BTG).
Study Status:
- Actively accruing
- More than 230 patients enrolled
Study Design:
- Randomized phase III trial (1:1)
- Planned enrollment: 411 patients
- More than 40 sites in 11 countries across Europe, expansion ongoing (contact us if you want to contribute!)
Treatment Arms:
- Lomustine (110 mg/m² every 6 weeks)
- Lomustine (110 mg/m² every 6 weeks) plus radiotherapy (35 Gy in 10 fractions)
Main Eligibility Criteria:
- Histologically confirmed glioblastoma, IDH wild-type (WHO 2021)
- First progression ≥6 months after the end of prior radiotherapy
- Radiologically measurable disease per RANO criteria, max. tumor diameter 5 cm
- WHO performance status of 0-2
Primary Endpoint:
- Overall survival
Secondary Endpoints:
- Progression-free survival
- Response rate
- Neurocognitive function
- Health-related quality of life
- Health economic parameters
Trial Registration:
Study Coordination:
- Principle investigator: Matthias Preusser
- Study co-coordinators: Giuseppe Minniti, Thomas Kazda
- Trial sponsor: EORTC – European Organisation for Research and Treatment of Cancer
Trial Funding:
- LEGATO has received funding from the European Union’s HORIZON-MISS-CANCER-2022-01 under grant agreement Nº (101103655).
More Information:
Study protocol:
Trial website:
Trial summary.”
Title: Lomustine with or without reirradiation for first progression of glioblastoma, LEGATO, EORTC-2227-BTG: study protocol for a randomized phase III study
Authors: Matthias Preusser, Tomáš Kazda, Emilie Le Rhun, Felix Sahm, Marion Smits, Jens Gempt, Johan AF Koekkoek, Angelo F Monti, Marcell Csanadi, János György Pitter, Helen Bulbek, Beatrice Fournier, Caroline Quoilin, Thierry Gorlia, Michael Weller, Giuseppe Minniti, European Organisation for Research, Treatment of Cancer (EORTC) Brain Tumor Group
Read the Full Article on Trials
You can also read: Re-Irradiation in Pediatric CNS Tumors: Balancing a Second Chance of Cure Against Long-Term Toxicity
